Intravitreal bevacizumab does not benefit patients with advanced neovascular age-related macular degeneration (AMD) and very poor vision, according to a new 21-patient study.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.
Learn more about writing for us
OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists!
© 2007-2013 OphthalmologyWeb
All rights reserved.